Latest / Mind & Medicine: Neuro Pharma Insights / Amisulpride The Antipsychotic That Works Differently

Transcript

Amisulpride The Antipsychotic That Works Differently · Mind & Medicine: Neuro Pharma Insights

• 0:00
  Speaker 1: Imagine a scenario, right that just totally breaks all the
• 0:03
  Speaker 1: conventional rules of medicine. I mean, say you have a
• 0:06
  Speaker 1: patient suffering from a really severe psychiatric condition.
• 0:09
  Speaker 2: Yeah, a complex case.
• 0:11
  Speaker 1: Exactly, And if you give them a massive dose of
• 0:14
  Speaker 1: a specific drug, it shuts down their hallucinations, which you
• 0:18
  Speaker 1: know makes sense. But if you take that exact same
• 0:21
  Speaker 1: drug and give them a tiny microscopic dose.
• 0:25
  Speaker 2: Like a fraction of the original amount of.
• 0:27
  Speaker 1: Right, a tiny dose, it cures a completely different symptom entirely.
• 0:30
  Speaker 1: It actually restores their motivation and like their emotional presence.
• 0:35
  Speaker 1: It's just a complete biological paradox.
• 0:37
  Speaker 2: It really is. It's the ultimate collision of molecular biology
• 0:40
  Speaker 2: and well macroeconomics strategy.
• 0:43
  Speaker 1: Yeah, and as we are going to explore today with you,
• 0:45
  Speaker 1: that specific biological paradox didn't just change patients' lives, it
• 0:50
  Speaker 1: served as the foundation for honestly one of the most lucrative,
• 0:54
  Speaker 1: air tight pharmaceutical monopoly structures in the world's most populous country.
• 0:58
  Speaker 2: Right, because we are looking at a mallic that is
• 1:00
  Speaker 2: so incredibly precise in how it navigates the human brain
• 1:04
  Speaker 2: that it's chemical geometry. I mean, it practically rights the
• 1:07
  Speaker 2: business contracts for the companies distributing it.
• 1:10
  Speaker 1: It's wild. So welcome to a brand new deep dive.
• 1:13
  Speaker 1: We are pulling insights today from an industry intelligence briefing
• 1:16
  Speaker 1: by Mind and Medicine Neuropharma Insights. Great source, Yeah, super detailed,
• 1:22
  Speaker 1: and our mission for you today is to explore a
• 1:24
  Speaker 1: drug called amsoul Pride. We're looking at its dual identity basically, right.
• 1:29
  Speaker 2: First as a biological tool and then as a business asset.
• 1:32
  Speaker 1: Exactly, First as this chemical master key that unlocks a
• 1:36
  Speaker 1: very specific door in the brain, and second as this
• 1:39
  Speaker 1: incredibly strategic afft in the high stakes world of pharmaceutical franchises.
• 1:44
  Speaker 2: Which is a huge industry.
• 1:45
  Speaker 1: Huge Now. In a previous deep dive into this space,
• 1:49
  Speaker 1: we explored eric pippersol, which, if you remember, acts kind
• 1:52
  Speaker 1: of like a volume dial.
• 1:53
  Speaker 2: For dopamine, right and modulates it.
• 1:55
  Speaker 1: Yeah, but today's molecule is different. It belongs to the
• 1:57
  Speaker 1: Benzmin class of antipsychotics, and its entire reputation is built
• 2:01
  Speaker 1: on well one word, really, exclusivity.
• 2:04
  Speaker 2: And you know, in neuropharmacology, exclusivity is historically very rare.
• 2:10
  Speaker 2: He totally if you look back at the history of
• 2:11
  Speaker 2: psychiatric medicine. The earliest interventions were essentially chemical carpet bombing. Right.
• 2:18
  Speaker 1: Okay, let's unpack this because understanding that history is just
• 2:21
  Speaker 1: crucial to seeing why amzol pride is such a big deal.
• 2:24
  Speaker 2: Yeah. It sets the stage.
• 2:25
  Speaker 1: Because the old approach wasn't so much a targeted treatment
• 2:30
  Speaker 1: as it was just an effort to overwhelm the nervous system.
• 2:34
  Speaker 1: Like if treating psychiatric conditions is like trying to fix
• 2:37
  Speaker 1: a complex switchboard.
• 2:39
  Speaker 2: Oh, that's a good analogy.
• 2:40
  Speaker 1: Yeah, the older drugs were like hitting the whole board
• 2:42
  Speaker 1: of a mallet. Right. Well, amocyl pride acts like a
• 2:45
  Speaker 1: highly precise tool.
• 2:46
  Speaker 2: That is a very fair assessment. Yeah, because we are
• 2:49
  Speaker 2: talking about the first generation antipsychotics discovered in the nineteen fifties,
• 2:53
  Speaker 2: things like.
• 2:54
  Speaker 3: Core promising, right, the early stuff.
• 2:56
  Speaker 2: Yeah, and these were actually synthesized originally as surgical sedatives
• 3:01
  Speaker 2: or antihistamines. Wait, like allergy medical basically, Yes, doctors essentially
• 3:06
  Speaker 2: noticed that these really powerful sedatives induced a state of
• 3:10
  Speaker 2: like artificial hibernation in agitated patients. Wow, and they just
• 3:14
  Speaker 2: ran with it. So when a patient took those older drugs,
• 3:17
  Speaker 2: the molecules would just flood the brain and indiscriminately bind
• 3:20
  Speaker 2: to almost everything they touched.
• 3:22
  Speaker 1: Just hitting every switch on the board exactly.
• 3:24
  Speaker 2: They would block dopamine receptors, which you know helped with hallucinations. Sure,
• 3:29
  Speaker 2: but they would simultaneously crash into histamine receptors, serotonin receptors,
• 3:34
  Speaker 2: and alpha adrenergic receptors.
• 3:36
  Speaker 1: So instead of a precision tool, you are literally using
• 3:39
  Speaker 1: a sledgehammer on this highly sensitive neural switchboard.
• 3:42
  Speaker 2: A sledgehammer that causes massive collateral damage. I mean, when
• 3:47
  Speaker 2: you indiscriminately block histamine receptors in the brain, for example,
• 3:50
  Speaker 2: the patient experiences this profound crushing lethargy, just exhausted all
• 3:56
  Speaker 2: the time, exhausted, and a massive increase in appetite. And
• 4:00
  Speaker 2: then when you hit the alpha adrenergic receptors, their blood
• 4:03
  Speaker 2: pressure drops every time they stand up.
• 4:05
  Speaker 1: Also, they get dizzy.
• 4:06
  Speaker 2: Super dizzy, prone to falling over. It's really rough.
• 4:09
  Speaker 1: And the tragic part is I mean for decades that
• 4:12
  Speaker 1: collateral damage was just considered the unavoidable cost of treating
• 4:16
  Speaker 1: severe mental illness.
• 4:17
  Speaker 2: Yeah, it was just the accepted trade off.
• 4:19
  Speaker 1: Like you trade the psychosis for fifty pounds a weight
• 4:22
  Speaker 1: gain and fourteen hours of sleep a day. But from
• 4:25
  Speaker 1: what the briefing says, msil Pride abandons that carpet bombing
• 4:29
  Speaker 1: approach entirely.
• 4:30
  Speaker 2: Completely abandons it.
• 4:31
  Speaker 1: It is essentially a targeted drone strike, right. It completely
• 4:34
  Speaker 1: ignores the histamine receptors. It just breezes right past the
• 4:38
  Speaker 1: serotonin and adrenergic receptor.
• 4:39
  Speaker 2: Yeah, it doesn't touch them.
• 4:41
  Speaker 1: It is designed to bind almost exclusively to dopamine, D
• 4:44
  Speaker 1: two and D three receptors. But I have to ask
• 4:49
  Speaker 1: why did older drugs hit so many receptors in the
• 4:52
  Speaker 1: first place. Was it just a lack of technological capability
• 4:55
  Speaker 1: back then, or was it a different medical philosophy.
• 4:57
  Speaker 2: It was mostly technological trantations on. We just didn't know
• 5:00
  Speaker 2: how to engineer molecules with that level of specificity yet.
• 5:04
  Speaker 1: Uh.
• 5:05
  Speaker 2: But what's fascinating here is how that molecular exclusivity transforms
• 5:09
  Speaker 2: the lived reality of the patient. I mean, we talk
• 5:12
  Speaker 2: about receptor binding affinities in a lab, which sounds super
• 5:15
  Speaker 2: clinical exactly, But for a human being trying to navigate
• 5:19
  Speaker 2: their day, this exclusivity means the absence of that heavy
• 5:23
  Speaker 2: chemical blanket, the hibernation you mentioned, right, We call it
• 5:26
  Speaker 2: a cleaner side effect profile in the industry, but really
• 5:30
  Speaker 2: it means cognitive preservation.
• 5:32
  Speaker 1: So it's the difference between feeling treated and feeling like
• 5:37
  Speaker 1: chemically lobotomized.
• 5:39
  Speaker 2: That's a strong way to put it, but yeah, accurate.
• 5:41
  Speaker 1: Because by leaving those other receptors alone, am cul pride
• 5:45
  Speaker 1: allows a patient to retain their mental sharpness, their wit,
• 5:49
  Speaker 1: you know, their ability to recall words quickly exactly.
• 5:52
  Speaker 2: They aren't constantly fighting through a thick mental fog just
• 5:55
  Speaker 2: to have a normal conversation. That's huge, it is, and
• 5:58
  Speaker 2: that ability to actively participate hate in life, to not
• 6:01
  Speaker 2: feel sedated, becomes critically important when we look at the
• 6:04
  Speaker 2: specific condition amsol Pride is most famous for treating, which
• 6:08
  Speaker 2: is schizophrenia.
• 6:10
  Speaker 1: Right now, for you listening, if you're familiar with schizophrenia,
• 6:13
  Speaker 1: you probably know about the positive.
• 6:14
  Speaker 2: Symptoms, the ones most people think of.
• 6:16
  Speaker 1: Yeah, the hallucinations, the delusions, the paranoia, and standard antipsychotics
• 6:22
  Speaker 1: handle those fairly well, right by suppressing dopamine in the.
• 6:25
  Speaker 2: Brain, yes, specifically in the mesolymbic pathway.
• 6:28
  Speaker 1: Okay, but the true heartbreak of schizophrenia, according to the sources,
• 6:33
  Speaker 1: lies in the negative symptoms.
• 6:34
  Speaker 2: Absolutely, the profound.
• 6:36
  Speaker 1: Social withdrawal, the flat affect, where like a person's face
• 6:40
  Speaker 1: and voice are just completely emptied of emotion.
• 6:43
  Speaker 2: It's devastating for families.
• 6:44
  Speaker 1: To watch, I can imagine. And there's this total paralyzing
• 6:47
  Speaker 1: lack of motivation to do anything, even just get out
• 6:50
  Speaker 1: of bed.
• 6:50
  Speaker 2: And those negative symptoms are notoriously resistant to chemical intervention.
• 6:54
  Speaker 2: In fact, if you use a carpet bombing drug that
• 6:57
  Speaker 2: suppresses dopamine globally across the brain, you often make those
• 7:01
  Speaker 2: negative symptoms significantly worse.
• 7:04
  Speaker 1: Wait, really the medicine makes it worse.
• 7:07
  Speaker 2: Yeah, because you might quiet the voices, but you further
• 7:09
  Speaker 2: deplete the patient's motivation and an emotional resonance by tanking
• 7:13
  Speaker 2: all their dopamine. Wow, you've stopped the act of crisis. Sure,
• 7:16
  Speaker 2: but you've left the person entirely hollowed out.
• 7:19
  Speaker 1: And this is exactly the biological paradox we mentioned at
• 7:22
  Speaker 1: the very start of the show. Here's where it gets
• 7:25
  Speaker 1: really interesting because amosol pride is widely celebrated because it
• 7:30
  Speaker 1: actually treats those stubborn negative symptoms.
• 7:33
  Speaker 2: Which is a game changer.
• 7:34
  Speaker 1: But it doesn't do it at the standard dose used
• 7:37
  Speaker 1: to fight hallucinations. It does it at this incredibly low
• 7:40
  Speaker 1: specific dose of exactly fifty milligrams.
• 7:43
  Speaker 2: Just a tiny amount.
• 7:45
  Speaker 1: Yeah, intuitively, this breaks all the rules you assume about medicine, right,
• 7:49
  Speaker 1: Usually a more difficult symptom requires a stronger intervention.
• 7:52
  Speaker 2: That's the logical assumption.
• 7:54
  Speaker 1: So how does giving a patient less of a drug
• 7:57
  Speaker 1: suddenly cure the hardest symptom to treat? It? Seems so bad?
• 8:00
  Speaker 2: This raises an important question and the answer lies in
• 8:03
  Speaker 2: the microscopic geography of the synapse.
• 8:05
  Speaker 1: Okay, take us there.
• 8:06
  Speaker 2: So to understand this, we have to look at how
• 8:08
  Speaker 2: neurons actually communicate. When we talk about dopamine, we aren't
• 8:12
  Speaker 2: just talking about a soup slashing around in the brain.
• 8:15
  Speaker 2: Dopamine is released from one neuron, It travels across a
• 8:18
  Speaker 2: tiny gap called the synapse, and it binds to receptors
• 8:22
  Speaker 2: on the next neuron to pass the signal along.
• 8:24
  Speaker 1: Like a chemical relay race.
• 8:26
  Speaker 2: Exactly like a relay race. Now, at high doses, amosol
• 8:29
  Speaker 2: pride floods the synapse and blocks the receiving receptors, the
• 8:33
  Speaker 2: D two and D three receptors on the post.
• 8:36
  Speaker 3: Synaptic neuron one kissing the baton.
• 8:38
  Speaker 2: Right, and that stops the excess dopamine signaling that causes
• 8:42
  Speaker 2: the hallucinations. But and this is the key, the neuron
• 8:46
  Speaker 2: that releases the dopamine also has its own receptors, we
• 8:49
  Speaker 2: would Yeah, we call these presynaptic autoreceptors.
• 8:53
  Speaker 1: So the neuron throwing the baton also has sensors on
• 8:56
  Speaker 1: its own hands.
• 8:57
  Speaker 2: That is a brilliant way to picture it. Actually, Yes,
• 8:59
  Speaker 2: And those auto receptors act like a.
• 9:01
  Speaker 3: Thermostat, okay, a thermostat.
• 9:03
  Speaker 2: When they sense that there's plenty of dopamine in the sinax,
• 9:07
  Speaker 2: they send a signal to the neurons saying, Okay, it's
• 9:09
  Speaker 2: getting warm in here, turn off the furnace, stop releasing dopamine.
• 9:12
  Speaker 1: Oh I see, which brings us to the fifty milligram
• 9:15
  Speaker 1: trick exactly, because at that incredibly low dose, a misol
• 9:19
  Speaker 1: pride doesn't have the strength to flood the whole brain
• 9:22
  Speaker 1: and block all those receiving neurons.
• 9:24
  Speaker 2: Not enough of the drug in the system.
• 9:25
  Speaker 1: Instead, it selectively binds to and blocks that presynaptic thermostat.
• 9:30
  Speaker 2: Yes, and by blocking the thermostat, the drug essentially blinds
• 9:35
  Speaker 2: the neuron.
• 9:36
  Speaker 1: Oh my go.
• 9:37
  Speaker 2: The neuron thinks, I don't send any dopamine out there.
• 9:40
  Speaker 2: It's freezing. We need to turn the furnace on full blast,
• 9:43
  Speaker 2: so it starts pumping way more dopamine into the synapse.
• 9:46
  Speaker 1: So a low dose of an antipsychotica drug literally designed
• 9:49
  Speaker 1: to block dopamine, is actually tricking the frontal cortex into
• 9:53
  Speaker 1: producing a massive dopamine boost.
• 9:55
  Speaker 2: It's completely counterintuitive, but yes.
• 9:57
  Speaker 1: And the frontal cortex is the exact region of the
• 10:00
  Speaker 1: brain responsible for motivation, for feeling joy, for engaging socially.
• 10:05
  Speaker 2: It is a phenomenal mechanism. The psychiatrist is using the
• 10:09
  Speaker 2: physical geometry of the molecule to orchestrate a highly localized
• 10:13
  Speaker 2: dopamine surge right where the patient needs it most.
• 10:16
  Speaker 1: That is just incredible.
• 10:18
  Speaker 2: That fifty milligram dose bridges the gap that almost every
• 10:21
  Speaker 2: other treatment misses. It wakes the patient up, It gives
• 10:23
  Speaker 2: them the internal drive to leave their room, to speak
• 10:25
  Speaker 2: with inflection, to participate in their own life again.
• 10:29
  Speaker 1: When you lay out the biology like that, I mean,
• 10:31
  Speaker 1: it feels like an absolute triumph of empathy in medical science.
• 10:34
  Speaker 2: It's a huge victory.
• 10:36
  Speaker 1: You are literally giving someone their humanity back. But and
• 10:40
  Speaker 1: here's the pivot. When a patient gets that drive back.
• 10:43
  Speaker 1: They don't just take this fifty milligram pill once and
• 10:46
  Speaker 1: move on.
• 10:47
  Speaker 2: Yeh, definitely not.
• 10:48
  Speaker 1: To maintain that connection to the world, they need that
• 10:51
  Speaker 1: dopamine boost every single morning, year after year.
• 10:55
  Speaker 2: And that biological necessity is the invisible bridge that carries
• 10:58
  Speaker 2: us from clinical medicine straight into the reality of pharmaceutical economics.
• 11:03
  Speaker 1: Which brings us to the business of brain.
• 11:04
  Speaker 2: Chemistry the other side of the coin.
• 11:06
  Speaker 1: Yeah, we are looking at a specific product manufactured by
• 11:10
  Speaker 1: Holy Evolution Pharma called Immasu Pride.
• 11:12
  Speaker 2: Fifty, very straightforward name.
• 11:14
  Speaker 1: Yeah, it's exactly what it sounds like, a precise fifty
• 11:17
  Speaker 1: milligram dose of amsoul pride. And the briefing notes it
• 11:21
  Speaker 1: comes packaged in these ten by ten blister packs and
• 11:24
  Speaker 1: it carries the WHO GMP certification, which means it meets
• 11:28
  Speaker 1: the World Health Organization's Good Manufacturing Practices.
• 11:31
  Speaker 2: And that certification is critical, particularly in the Indian market.
• 11:34
  Speaker 1: Why is that so important there.
• 11:36
  Speaker 2: Because it guarantees a baseline of international quality control. It
• 11:40
  Speaker 2: tells the doctors prescribing it that they aren't dealing with
• 11:43
  Speaker 2: a volatile or unverified generic drug.
• 11:46
  Speaker 3: They know it's the real deal, exactly.
• 11:48
  Speaker 2: It builds instant trust.
• 11:49
  Speaker 1: But the strategy behind Amos to Pride fifty isn't just
• 11:52
  Speaker 1: about making a high quality pill, right, It's about how
• 11:56
  Speaker 1: that pill is actually sold.
• 11:57
  Speaker 2: The distribution model is fascinating.
• 12:00
  Speaker 1: Yeah, Holy Evolution Pharma makes this product available for what
• 12:04
  Speaker 1: are known as NEUROPCD franchise partners, and they offer these
• 12:08
  Speaker 1: partners monopoly rights across specific regions in India.
• 12:12
  Speaker 3: Which is a huge incentive, oh for sure.
• 12:14
  Speaker 1: Now for you or anyone outside of the Indian pharmaceutical industry,
• 12:18
  Speaker 1: the acronym PCD can sound a little jarring. It stands
• 12:21
  Speaker 1: for propagandacum distribution.
• 12:24
  Speaker 2: It does sound really jarring to modern ears. I mean propaganda.
• 12:27
  Speaker 1: Yeah, sounds like a political campaign.
• 12:28
  Speaker 2: But in this context, the word propaganda isn't being used
• 12:31
  Speaker 2: in this sinister political sense at all. It's actually a
• 12:35
  Speaker 2: legacy term from older British pharmaceutical practices. Oh interesting, Yeah,
• 12:40
  Speaker 2: propaganda simply means to propagate information or what we would
• 12:43
  Speaker 2: call medical detailing or pharmaceutical sales today.
• 12:46
  Speaker 1: Okay, so a PCB franchise partner isn't running like a
• 12:51
  Speaker 1: propaganda machine in the streets. They're essentially a highly specialized
• 12:55
  Speaker 1: regional sales and distribution.
• 12:57
  Speaker 2: Team, precisely because India is a massive, complex market. We're
• 13:02
  Speaker 2: talking over one point four billion people and highly distinct
• 13:06
  Speaker 2: regional dynamics.
• 13:07
  Speaker 1: You can't just run that from one office exactly.
• 13:10
  Speaker 2: A single centralized pharmaceutical manufacturer like Holy Evolution Pharma, they
• 13:14
  Speaker 2: can't possibly hire enough sales reps to build personal relationships
• 13:18
  Speaker 2: with every single psychiatrist in every single state.
• 13:21
  Speaker 1: It would be impossible.
• 13:22
  Speaker 2: So they decentralize. They offer a franchise model.
• 13:24
  Speaker 1: I see, so if I'm an entrepreneur in say tomil Nadu,
• 13:28
  Speaker 1: I can become a PCD partner. I buy Amy Spride
• 13:31
  Speaker 1: fifty wholesale from Holy Evolution, and in return, they give
• 13:34
  Speaker 1: me the exclusive rights to be the sole distributor of
• 13:37
  Speaker 1: that specific brand in my territory. I hold the monopoly.
• 13:40
  Speaker 2: You're the only game in town for that brand.
• 13:42
  Speaker 1: So my job is to take the scientific literature, the
• 13:45
  Speaker 1: quote unquote propaganda, go to the local psychiatrists, explain the
• 13:50
  Speaker 1: brilliant fifty milligram thermostat mechanism we just talked about, and
• 13:54
  Speaker 1: convince them to prescribe my product.
• 13:56
  Speaker 2: And this is where the exclusivity of the molecule perfectly
• 14:00
  Speaker 2: mirrors the exclusivity of the business contract. How so, we'll
• 14:03
  Speaker 2: think about it. Why would an entrepreneur take on the
• 14:06
  Speaker 2: financial risk of buying bulk inventory and spending months pitching.
• 14:09
  Speaker 1: To doctors because it's a guaranteed hit.
• 14:11
  Speaker 2: Because Holy Evolution Pharma is handing them a product with
• 14:14
  Speaker 2: an incredibly specific, underserved market. Psychiatrists have clinics full of
• 14:20
  Speaker 2: patients suffering from the negative symptoms of schizophrenia.
• 14:23
  Speaker 1: And nothing else works, right.
• 14:25
  Speaker 2: They are desperate for a tool.
• 14:26
  Speaker 1: That works, so the demand is already baked in. You
• 14:28
  Speaker 1: don't have to convince the doctor that the disease exists
• 14:31
  Speaker 1: or even that it needs treating. You just have to
• 14:33
  Speaker 1: show them you hold the precise fifty milligram key to
• 14:36
  Speaker 1: solving it.
• 14:37
  Speaker 2: Yes, And once you convince that psychiatrist, you unlock the
• 14:41
  Speaker 2: most powerful economic engine in the pharmaceutical industry, which is
• 14:44
  Speaker 2: the chronic reorder cycle. Because schizophrenia is not an infection,
• 14:49
  Speaker 2: it doesn't just clear up after a ten day course
• 14:51
  Speaker 2: of antbiotics, right, It's.
• 14:52
  Speaker 1: A lifelong condition exactly, So what does this all mean
• 14:55
  Speaker 1: for the patient? Really? Because I really want to push
• 14:57
  Speaker 1: back on this framing for a second. Honestly, it feels
• 15:01
  Speaker 1: incredibly cold.
• 15:02
  Speaker 2: I understand why it's say that.
• 15:03
  Speaker 1: Because we just spent twenty minutes marveling at how this
• 15:06
  Speaker 1: molecule gracefully tricks the brain into restoring a patient's capacity
• 15:12
  Speaker 1: to feel emotion, you know, to engage with their family again.
• 15:16
  Speaker 2: It's a beautiful medical achievement.
• 15:18
  Speaker 1: It is, And now we are looking at that exact
• 15:21
  Speaker 1: same patient as a guaranteed lifelong revenue stream. I mean,
• 15:25
  Speaker 1: the ten x ten blister pack isn't just a convenient
• 15:27
  Speaker 1: way to hold pills. It's a physical subscription model.
• 15:30
  Speaker 2: That's one way to look at it.
• 15:31
  Speaker 1: Yes, it just feels very dystopian to look at a
• 15:33
  Speaker 1: lifelong mental illness as the ultimate financial asset for an entrepreneur.
• 15:38
  Speaker 2: You're entirely justified in feeling that friction. It is uncomfortable
• 15:41
  Speaker 2: to talk about. But if we connect this to the
• 15:44
  Speaker 2: bigger picture, it is also the unfiltered reality of how
• 15:48
  Speaker 2: life saving medicine physically reaches patients in a massive, privatized
• 15:52
  Speaker 2: healthcare ecosystem.
• 15:53
  Speaker 1: Right, the logistics of it.
• 15:54
  Speaker 2: The incentive structure requires profitability. If you want a regional
• 15:58
  Speaker 2: distributor to drive three hours outside of a major city
• 16:02
  Speaker 2: to ensure a rural psychiatric clinic is fully stocked with
• 16:06
  Speaker 2: Amasol Pride.
• 16:06
  Speaker 1: They need to get paid.
• 16:07
  Speaker 2: That distributor needs a cast iron guarantee that their investment
• 16:10
  Speaker 2: of time and money will pay off.
• 16:12
  Speaker 1: And the guarantee is the chronic nature of the illness itself.
• 16:16
  Speaker 1: Because secured patient doesn't need a reorder next month.
• 16:20
  Speaker 2: That is the hard economic truth. A drug that perfectly
• 16:23
  Speaker 2: manages a condition over a thirty year lifespan is exponentially
• 16:27
  Speaker 2: more valuable to a franchise partner than a drug that
• 16:30
  Speaker 2: cures the disease outright.
• 16:31
  Speaker 1: Wow.
• 16:32
  Speaker 2: And what makes Amazol Pride such a flawless product for
• 16:35
  Speaker 2: this specific franchise model is its side effect profile.
• 16:39
  Speaker 1: Because it's a clean drug, like we talked about earlier.
• 16:42
  Speaker 2: Exactly with the older carpet bombing medications, patients would constantly
• 16:46
  Speaker 2: stop taking.
• 16:47
  Speaker 1: Their pills because the side effects were unbearable.
• 16:50
  Speaker 2: They would gain fifty pounds, or they felt soucidated, they
• 16:52
  Speaker 2: couldn't stay awake at their job, so they just quit taking.
• 16:54
  Speaker 1: It, which is terrible for the patient's health obviously, but
• 16:58
  Speaker 1: from a business perspective, it also disrupts the distributor's revenue stream.
• 17:02
  Speaker 2: Exactly the compliance rate for older antipsychotics was abysmal. But
• 17:08
  Speaker 2: because amsol Pride is so selective, because it leaves the
• 17:11
  Speaker 2: histamine and serotonin receptors totally alone, the patient doesn't experience
• 17:16
  Speaker 2: that agonizing weight gain or cognitive.
• 17:18
  Speaker 3: Blunting You feel like themselves.
• 17:19
  Speaker 2: They do. Therefore, they actually keep taking the medication every
• 17:23
  Speaker 2: single day.
• 17:23
  Speaker 1: So the very mechanism that makes the drug so incredibly humane,
• 17:28
  Speaker 1: right it's chemical selectivity, is the exact same mechanism they
• 17:32
  Speaker 1: guarantees the distributor's thirty year recurring revenue stream.
• 17:35
  Speaker 2: It's two sides of the same coin.
• 17:37
  Speaker 1: The patient stays on the drug because their quality of
• 17:39
  Speaker 1: life is better, and the franchise secures their regional monopoly
• 17:43
  Speaker 1: because the patient never stops buying the blister packs.
• 17:45
  Speaker 2: The clinical efficacy and the commercial strategy are totally locked together.
• 17:50
  Speaker 2: You cannot separate the microscopic geometry of the D two
• 17:53
  Speaker 2: receptor from the macroeconomic structure of the PCD franchise agreement.
• 17:58
  Speaker 1: They just reinforce one another perfectly.
• 18:00
  Speaker 2: They do. Holy evolution. Pharma isn't just selling a chemical.
• 18:04
  Speaker 2: They are selling a highly predictable, highly tolerable, lifelong habit.
• 18:09
  Speaker 1: It is wild to think about it that way. Just
• 18:12
  Speaker 1: the shape of a molecule in the frontal cortex dictates
• 18:15
  Speaker 1: the terms of a business contract in a corporate office
• 18:18
  Speaker 1: miles away.
• 18:19
  Speaker 2: It really is a masterclass in market alignment.
• 18:21
  Speaker 1: We have covered a truly massive amount of ground today.
• 18:25
  Speaker 1: I mean, we started by looking at the history of
• 18:26
  Speaker 1: psychiatric medicine, right, moving away from the sledgehammer approach of
• 18:30
  Speaker 1: older drugs that caused so much collateral.
• 18:32
  Speaker 2: Damage, the chemical hibernation, yeah, and.
• 18:34
  Speaker 1: Moving toward the precision drone strike of amicyl pride. And
• 18:38
  Speaker 1: we explored that brilliant paradox of how a tiny fifty
• 18:40
  Speaker 1: milligram dose can block a pre synaptic thermostat tricking the brain,
• 18:44
  Speaker 1: tricking the brain into producing a dopamine boost that cures
• 18:47
  Speaker 1: the devastating negative symptoms of schizophrenia.
• 18:49
  Speaker 2: And from there we zoomed out to the sheer scale
• 18:52
  Speaker 2: of the Indian pharmaceutical market, looking at how that exact
• 18:56
  Speaker 2: clinical precision serves as the foundation for the propagandacum distribution
• 19:00
  Speaker 2: franchise model.
• 19:01
  Speaker 1: Right. And for you listening, this is exactly why it
• 19:04
  Speaker 1: is so crucial to look at industry intelligence like this.
• 19:07
  Speaker 1: It is never just about the science in a vacuum.
• 19:11
  Speaker 1: You know, there is a single intentional change in how
• 19:15
  Speaker 1: a molecule binds to a receptor ripples outward. It changes
• 19:19
  Speaker 1: the lived reality of a patient waking up in the morning,
• 19:22
  Speaker 1: It changes the tools a psychiatrist has in their arsenal,
• 19:25
  Speaker 1: and it actively builds global monopolized business empires based on
• 19:29
  Speaker 1: decades of guaranteed reorders.
• 19:31
  Speaker 2: It is a deeply interconnected system, and you know, it
• 19:34
  Speaker 2: leaves us with a rather profound tension to consider what's that? Well,
• 19:37
  Speaker 2: we have seen how the neuropharma franchise model thrives on predictability, right,
• 19:42
  Speaker 2: it is structurally designed to reward treatments that perfectly manage
• 19:45
  Speaker 2: chronic conditions over a lifetime. But we have to ask
• 19:49
  Speaker 2: ourselves if the most lucrative business models in the world
• 19:52
  Speaker 2: inherently rely on lifelong maintenance, what happens to the financial
• 19:57
  Speaker 2: incentive to seek permanent cures?
• 19:58
  Speaker 1: Oh, it's heavy.
• 19:59
  Speaker 2: Does the sheer profitability of a highly tolerable, daily maintenance
• 20:04
  Speaker 2: drug subtly slow down the race to find a way
• 20:07
  Speaker 2: to eradicate the disease entirely?
• 20:09
  Speaker 1: Man? That is a phenomenal and honestly somewhat haunting question
• 20:14
  Speaker 1: To end on. It forces you to look at the
• 20:17
  Speaker 1: medicine in your cabinet from an entirely new angle.
• 20:20
  Speaker 2: It really does.
• 20:21
  Speaker 1: We have come a very long way from taking a
• 20:22
  Speaker 1: sledgehammer to the brain switchboard, but the highly tuned, incredibly
• 20:26
  Speaker 1: profitable system we have built around these modern precision tools
• 20:30
  Speaker 1: brings its own complex wires that we still need to untangle.
• 20:33
  Speaker 1: Thank you so much for joining us on this deep dive.
• 20:35
  Speaker 1: Keep questioning the systems around you, keep looking for those connections,
• 20:38
  Speaker 1: and we will get you next time.